SIGHT Stock Overview
A clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
GenSight Biologics S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.32 |
52 Week High | €1.04 |
52 Week Low | €0.30 |
Beta | 2.12 |
1 Month Change | -19.80% |
3 Month Change | -32.62% |
1 Year Change | -63.08% |
3 Year Change | -96.19% |
5 Year Change | -78.09% |
Change since IPO | -96.12% |
Recent News & Updates
Recent updates
Is There An Opportunity With GenSight Biologics S.A.'s (EPA:SIGHT) 30% Undervaluation?
Dec 22Is GenSight Biologics S.A. (EPA:SIGHT) Trading At A 39% Discount?
Sep 20Health Check: How Prudently Does GenSight Biologics (EPA:SIGHT) Use Debt?
Aug 17Rock star Growth Puts GenSight Biologics (EPA:SIGHT) In A Position To Use Debt
Aug 04GenSight Biologics S.A. (EPA:SIGHT) Shares Could Be 27% Below Their Intrinsic Value Estimate
Jun 14GenSight Biologics S.A. (EPA:SIGHT): Is Breakeven Near?
May 10Analysts Expect Breakeven For GenSight Biologics S.A. (EPA:SIGHT) Before Long
Feb 02A Quick Analysis On GenSight Biologics' (EPA:SIGHT) CEO Salary
Dec 09Shareholder Returns
SIGHT | FR Biotechs | FR Market | |
---|---|---|---|
7D | -14.6% | -12.8% | -6.3% |
1Y | -63.1% | -28.4% | -2.4% |
Return vs Industry: SIGHT underperformed the French Biotechs industry which returned -28.4% over the past year.
Return vs Market: SIGHT underperformed the French Market which returned -2.4% over the past year.
Price Volatility
SIGHT volatility | |
---|---|
SIGHT Average Weekly Movement | 5.9% |
Biotechs Industry Average Movement | 6.8% |
Market Average Movement | 4.6% |
10% most volatile stocks in FR Market | 9.1% |
10% least volatile stocks in FR Market | 2.6% |
Stable Share Price: SIGHT's share price has been volatile over the past 3 months.
Volatility Over Time: SIGHT's weekly volatility has decreased from 17% to 6% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 16 | Laurence Rodriguez | www.gensight-biologics.com |
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration.
GenSight Biologics S.A. Fundamentals Summary
SIGHT fundamental statistics | |
---|---|
Market cap | €32.08m |
Earnings (TTM) | -€26.22m |
Revenue (TTM) | €2.96m |
10.8x
P/S Ratio-1.2x
P/E RatioIs SIGHT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SIGHT income statement (TTM) | |
---|---|
Revenue | €2.96m |
Cost of Revenue | €0 |
Gross Profit | €2.96m |
Other Expenses | €29.18m |
Earnings | -€26.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 23, 2024
Earnings per share (EPS) | -0.26 |
Gross Margin | 100.00% |
Net Profit Margin | -884.62% |
Debt/Equity Ratio | -70.7% |
How did SIGHT perform over the long term?
See historical performance and comparison